Roche pledges $700 million to join research on the drug bexobrutideg.
Roche joins Californian Nurix oncology programme
Keystone-SDA
Swiss pharmaceutical giant Roche is shelling out $700 million to join the research of Californian counterpart Nurix Therapeutics on the drug bexobrutideg.
Generated with artificial intelligence.
This content was published on
Roche stakes $700M on Nurix’s protein-degrading drug
Nurix to work with Roche on BTK degrader in pact worth up to $2.3B
Nurix Therapeutics Gains Ground As Roche Partnership Targets Growing B-Cell Blood Cancer Market - Nurix T
Roche Inks $2.3 Billion Deal, Sending Biotech Stock Flying
Roche fecha acordo de US$ 2,3 bilhões para remédio contra câncer
隆基绿能：控股股东李振国解除质押1.55亿股-36氪
EXCLUSIVE: Scienture Expands Coverage For Opioid Overdose Treatment Ahead Of Commercial Launch - Scientur
$10. 6 billion deal: GSK to buy US cancer specialist Nuvalent
Il franchising ematologico di base di BeOne Medicines guida la prossima era dell'innovazione oncologica delle cellule B all'EHA 2026
Gsk acquisisce Nuvalent per 10,6 miliardi nel top deal degli ultimi dieci anni
(Bloomberg) -- Roche Holding AG agreed to pay Nurix Therapeutics Inc. as much as $2.3 billion for rights to an experimental…
Potentially worth up to $2.3 billion, the collaboration is a bet that drugs able to eliminate the “BTK” enzyme will prove…
Roche is set to pay Nurix Therapeutics $700 million upfront to collaborate on a BTK degrader for B-cell malignancies.
Nurix Therapeutics and Roche sign a BTK degrader partnership worth up to $2.3 billion, supporting Phase 3 plans for bexobrutideg.
Shares bounded off their 50-day line Monday after inking a deal with Roche for a BTK-degrading drug.
O medicamento, utilizado para tratar vários tipos de câncer no sangue, como a leucemia linfocítica crônica, é um degradador de…
